HomeThe Column

The Column

It Is Thumbs Up for Cell Therapy in Japan

Philip Carrigan

It was recently reported that three large Japanese pharmaceutical companies – Fujifilm, Takeda Pharmaceutical and Astellas – have struck significant deals in the field of cell therapy as they seek a competitive advantage in this emerging area of pharmaceuticals. The Japanese government and corporations are betting big that cell therapy will be the answer to a number of tough challenges, such as a rapidly aging population, a concern regarding the availability of blood, and the need for innovative products that will carry pharma companies beyond 2020 and 2030 ...